Thymosin Alfa 1 in Recipients of Allogeneic Hematopoietic Transplantation for Hematological Malignancies

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
The purpose of this trial is to determine safety and efficacy of 16 weeks treatment with thymosin alpha 1 given at 1.6 mg dose once daily by subcutaneous injection in adult patients with hematological undergone allogenic bone marrow transplantation and CMV positive. The efficacy will be explored assessing the ability of thymosin alpha1 to prevent the infection complications.
Epistemonikos ID: 5341a5306f294a3545c2a0b3da6776e156e6253f
First added on: May 04, 2024